Support for the preclinical development of EIF4A inhibitors rocaglamide and didesmethylrocaglamide. (toxiciology services to support preclinical drug development) POP 09/23/2020-09/22/2021.
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $588,615
Award facts
- Contract value 24% obligated
-
- $588,615.00 Current, with exercised options
- $2,425,017.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $588,615 |
About this award
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $2.4 million delivery order against the Toxicology of Drugs Developed for Cancer Patients master IDIQ contract to IIT Research Institute. Under this order, IIT Research Institute will provide toxicology services to support the preclinical development of EIF4A inhibitors rocaglamide and didesmethylrocaglamide from September 2020 through September 2023 in Chicago, Illinois. The Toxicology of Drugs Developed for Cancer Patients master IDIQ was designed to support the National Cancer Institute's work advancing promising new anti-cancer therapies through preclinical testing, of which this order is an example. No subcontractors or set aside designations were indicated.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 23, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $588,615 on 75N91020F00001. Its potential value, with all options, is $2,425,017.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under HHSN261201600015I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award